aTyr Pharma Inc. (LIFE)
Company Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.
The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors.
It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.
The company was incorporated in 2005 and is headquartered in San Diego, California.
| Country | United States |
| IPO Date | May 7, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Sanjay S. Shukla |
Contact Details
Address: 3545 John Hopkins Court San Diego, California United States | |
| Website | https://www.atyrpharma.com |
Stock Details
| Ticker Symbol | LIFE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001339970 |
| CUSIP Number | 002120202 |
| ISIN Number | US0021202025 |
| Employer ID | 20-3435077 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sanjay S. Shukla M.D., M.S. | President, Chief Executive Officer & Director |
| Jill M. Broadfoot | Chief Financial Officer |
| Ashlee Dunston | Director of Investor Relations & Corporate Communications |
| Danielle Campbell | Vice President of Human Resource |
| Dr. David J. King Ph.D. | Scientific Consultant |
| Dr. Leslie Nangle Ph.D. | Vice President of Research |
| Dr. Ying J. Buechler Ph.D. | Executive Director of Biologics Development & Manufacturing |
| Nancy E. Denyes Krueger | General Counsel & Corporate Secretary |
| Peter Villiger | Vice President of Corporate Development |
| Xiang-Lei Yang Ph.D. | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 08, 2025 | 8-K/A | [Amend] Current Report |
| Aug 07, 2025 | S-8 | Filing |
| Aug 07, 2025 | S-3 | Filing |
| Aug 07, 2025 | 10-Q | Quarterly Report |
| Aug 07, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jul 17, 2025 | SCHEDULE 13G | Filing |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 07, 2025 | 10-Q | Quarterly Report |
| May 07, 2025 | 8-K | Current Report |